These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 26011424)

  • 1. The effect of recombinant erythropoietin on plasma brain derived neurotrophic factor levels in patients with affective disorders: a randomised controlled study.
    Vinberg M; Miskowiak K; Hoejman P; Pedersen M; Kessing LV
    PLoS One; 2015; 10(5):e0127629. PubMed ID: 26011424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of recombinant erythropoietin on inflammatory markers in patients with affective disorders: A randomised controlled study.
    Vinberg M; Weikop P; Olsen NV; Kessing LV; Miskowiak K
    Brain Behav Immun; 2016 Oct; 57():53-57. PubMed ID: 27181179
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant human erythropoietin for treating treatment-resistant depression: a double-blind, randomized, placebo-controlled phase 2 trial.
    Miskowiak KW; Vinberg M; Christensen EM; Bukh JD; Harmer CJ; Ehrenreich H; Kessing LV
    Neuropsychopharmacology; 2014 May; 39(6):1399-408. PubMed ID: 24322509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of Erythropoietin on Hippocampal Volume and Memory in Mood Disorders.
    Miskowiak KW; Vinberg M; Macoveanu J; Ehrenreich H; Køster N; Inkster B; Paulson OB; Kessing LV; Skimminge A; Siebner HR
    Biol Psychiatry; 2015 Aug; 78(4):270-7. PubMed ID: 25641635
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of recombinant human erythropoietin on cognition and neural activity in remitted patients with mood disorders and first-degree relatives of patients with psychiatric disorders: a study protocol for a randomized controlled trial.
    Petersen JZ; Schmidt LS; Vinberg M; Jørgensen MB; Hageman I; Ehrenreich H; Knudsen GM; Kessing LV; Miskowiak KW
    Trials; 2018 Nov; 19(1):611. PubMed ID: 30400939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neural correlates of improved executive function following erythropoietin treatment in mood disorders.
    Miskowiak KW; Vinberg M; Glerup L; Paulson OB; Knudsen GM; Ehrenreich H; Harmer CJ; Kessing LV; Siebner HR; Macoveanu J
    Psychol Med; 2016 Jun; 46(8):1679-91. PubMed ID: 26996196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of erythropoietin on depressive symptoms and neurocognitive deficits in depression and bipolar disorder.
    Miskowiak KW; Vinberg M; Harmer CJ; Ehrenreich H; Knudsen GM; Macoveanu J; Hansen AR; Paulson OB; Siebner HR; Kessing LV
    Trials; 2010 Oct; 11():97. PubMed ID: 20942940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant human erythropoietin to target cognitive dysfunction in bipolar disorder: a double-blind, randomized, placebo-controlled phase 2 trial.
    Miskowiak KW; Ehrenreich H; Christensen EM; Kessing LV; Vinberg M
    J Clin Psychiatry; 2014 Dec; 75(12):1347-55. PubMed ID: 25099079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BDNF, interleukin-6, and salivary cortisol levels in depressed patients treated with desvenlafaxine.
    Ninan PT; Shelton RC; Bao W; Guico-Pabia CJ
    Prog Neuropsychopharmacol Biol Psychiatry; 2014 Jan; 48():86-91. PubMed ID: 24096053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Variable alterations in plasma erythropoietin and brain-derived neurotrophic factor levels in patients with major depressive disorder with and without a history of suicide attempt.
    Lee BH; Park YM; Hwang JA; Kim YK
    Prog Neuropsychopharmacol Biol Psychiatry; 2021 Aug; 110():110324. PubMed ID: 33857523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of erythropoietin on memory-relevant neurocircuitry activity and recall in mood disorders.
    Miskowiak KW; Macoveanu J; Vinberg M; Assentoft E; Randers L; Harmer CJ; Ehrenreich H; Paulson OB; Knudsen GM; Siebner HR; Kessing LV
    Acta Psychiatr Scand; 2016 Sep; 134(3):249-59. PubMed ID: 27259062
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of erythropoietin on cognitive impairment and prefrontal cortex activity across affective disorders: A randomized, double-blinded, placebo-controlled trial.
    Macoveanu J; Petersen JZ; Mariegaard J; Jespersen AE; Cramer K; Bruun CF; Madsen HØ; Jørgensen MB; Vinberg M; Fisher PM; Knudsen GM; Hageman I; Ehrenreich H; Kessing LV; Miskowiak KW
    J Psychopharmacol; 2024 Apr; 38(4):362-374. PubMed ID: 38519416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of erythropoietin on body composition and fat-glucose metabolism in patients with affective disorders.
    Vinberg M; Højman P; Pedersen BK; Kessing LV; Miskowiak KW
    Acta Neuropsychiatr; 2018 Dec; 30(6):342-349. PubMed ID: 29880069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brain-derived neurotrophic factor and subcallosal deep brain stimulation for refractory depression.
    Ramasubbu R; Vecchiarelli HA; Hill MN; Kiss ZH
    World J Biol Psychiatry; 2015 Feb; 16(2):135-8. PubMed ID: 25226864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma brain derived neurotrophic factor (BDNF) and response to ketamine in treatment-resistant depression.
    Haile CN; Murrough JW; Iosifescu DV; Chang LC; Al Jurdi RK; Foulkes A; Iqbal S; Mahoney JJ; De La Garza R; Charney DS; Newton TF; Mathew SJ
    Int J Neuropsychopharmacol; 2014 Feb; 17(2):331-6. PubMed ID: 24103211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Electroconvulsive therapy improves clinical manifestations of treatment-resistant depression without changing serum BDNF levels.
    Rapinesi C; Kotzalidis GD; Curto M; Serata D; Ferri VR; Scatena P; Carbonetti P; Napoletano F; Miele J; Scaccianoce S; Del Casale A; Nicoletti F; Angeletti G; Girardi P
    Psychiatry Res; 2015 Jun; 227(2-3):171-8. PubMed ID: 25910420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Both Serum Brain-Derived Neurotrophic Factor and Interleukin-6 Levels Are Not Associated with Therapeutic Response to Lamotrigine Augmentation Therapy in Treatment-Resistant Depressive Disorder.
    Kagawa S; Mihara K; Suzuki T; Nagai G; Nakamura A; Nemoto K; Kondo T
    Neuropsychobiology; 2017; 75(3):145-150. PubMed ID: 29332095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brain-derived neurotrophic factor serum concentrations in acute depressive patients increase during lithium augmentation of antidepressants.
    Ricken R; Adli M; Lange C; Krusche E; Stamm TJ; Gaus S; Koehler S; Nase S; Bschor T; Richter C; Steinacher B; Heinz A; Rapp MA; Borgwardt S; Hellweg R; Lang UE
    J Clin Psychopharmacol; 2013 Dec; 33(6):806-9. PubMed ID: 24018547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma Brain-Derived Neurotrophic Factor Levels in First-Episode and Recurrent Major Depression and before and after Bright Light Therapy in Treatment-Resistant Depression.
    Kosanovic Rajacic B; Sagud M; Begic D; Nikolac Perkovic M; Dvojkovic A; Ganoci L; Pivac N
    Biomolecules; 2023 Sep; 13(9):. PubMed ID: 37759825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation of plasma brain-derived neurotrophic factor and metabolic profiles in drug-naïve patients with bipolar II disorder after a twelve-week pharmacological intervention.
    Lee SY; Chen SL; Chang YH; Chen PS; Huang SY; Tzeng NS; Wang CL; Wang LJ; Lee IH; Wang TY; Chen KC; Yang YK; Hong JS; Lu RB
    Acta Psychiatr Scand; 2015 Feb; 131(2):120-8. PubMed ID: 25131388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.